It has been hypothesized by some authors that the efficacy of PD-1 blockade is linked to the mutational burden and infiltrating effector cells in the tumor bed, which happen to be relatively lower in MM compared to solid tumors [38–40]. The gene discussed is PDCD1; the disease is neoplasm.